Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 1 · 14.3%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Recombinant human soluble thrombomodulin vs heparin

Adverse events · DIC

It is very uncertain whether recombinant human soluble thrombomodulin changes adverse events compared with heparin (very low certainty).

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
RR 0.88 [0.35, 2.2]
1 study · 231 participants
Very low

Recombinant human soluble thrombomodulin vs heparin

Bleeding · DIC

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 234 participants
Very low

Recombinant human soluble thrombomodulin vs heparin

Resolution of respiratory failure · DIC

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human soluble thrombomodulin vs heparin

Renal failure · DIC

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human soluble thrombomodulin vs heparin

Shock · DIC

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human soluble thrombomodulin vs heparin

Overall mortality · DIC

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 234 participants
GRADE not reported

Recombinant human soluble thrombomodulin vs heparin

Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC

It is very uncertain whether recombinant human soluble thrombomodulin changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
RR 0.85 [0.54, 1.36]
1 study · 227 participants
Very low